PACKAGE LEAFLET: INFORMATION FOR THE USER Espranor 2mg Oral Lyophilisate Espranor 8 mg Oral Lyophilisate buprenorphine

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to
 - others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See Section 4.

What is in this leaflet:

- 1. What Espranor is and what it is used for
- 2. What you need to know before you take Espranor
- 3. How to take Espranor
- 4. Possible side effects
- 5. How to store Espranor
- 6. Contents of the pack and other information

1. What Espranor is and what it is used for

Espranor oral lyophilisate is a freeze-dried wafer which dissolves rapidly on the tongue.

Espranor is used in adults and adolescent over 15 years of age, as part of a medical, social and psychological treatment programme for addiction.

Espranor contains buprenorphine, an opioid (narcotic) analgesic. When it is used for the treatment of patients addicted to opiate (narcotic) drugs, such as morphine or heroin, it acts as a substitute for these drugs and therefore aids the patient in withdrawing from them over a period of time.

If treatment is stopped abruptly, withdrawal symptoms can occur.

2. What you need to know before you take Espranor

Espranor is not interchangeable with other oral buprenorphine products and the dose of Espranor may differ from the dose of other buprenorphine products

Do not take Espranor if:

- You are allergic (hypersensitive) to buprenorphine or any of the other ingredients in Espranor (see section 6)
- You have severe breathing problems or are having an acute asthma attack
- You have severe liver problems
- You are alcohol dependent or suffer from acute alcoholism including 'the shakes' or hallucinations
- You are pregnant (unless your doctor tells you to take it)
- You have recently had a head injury or have a condition that causes pressure to build up in your head

• You are breast feeding a baby

Warnings and Precautions

Talk to your doctor, pharmacist or nurse before taking Espranor:

- If you suffer breathing problems e.g. asthma
- If you have liver problems
- If you have kidney problems
- If you have low blood pressure
- If you have a urinary disorder (especially linked to enlarged prostrate in men)
- If you have thyroid problems
- If you have adrenocortical disorder (e.g. Addison's disease)
- If you have depression or other conditions that are treated with antidepressants. The use of these medicines together with Espranor can lead to serotonin syndrome, a potentially life-threatening condition (see "Other medicines and Espranor").

If any of the above applies to you, please tell your doctor before taking Espranor as your doctor may need to reduce your dose of Espranor or you may need additional treatment to control it.

Important things to be aware of:

Additional monitoring

You may be more closely monitored by your doctor if you are below the age of 18. Espranor should not be given to children or adolescents under 15 years old.

Misuse, abuse and diversion

This medicine can be a target for people who abuse prescription medicines, and should be kept in a safe place to protect it from theft. Do not give this medicine to anyone else. It can cause death or otherwise harm them.

Breathing problems

Some people have died from respiratory failure (inability to breathe) because they misused this medicine or took it in combination with other central nervous system depressants, such as alcohol, benzodiazepines (tranquilisers), or other opioids.

Sleep-related breathing disorders

Espranor can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor.

Dependence

This product can cause dependence.

Withdrawal symptoms

This product can cause withdrawal symptoms if you take it less than six hours after you use a short-acting opioid (e.g. morphine, heroin) or less than 24 hours after you use a long-acting opioid such as methadone.

This medicine can also cause withdrawal symptoms if you stop taking it abruptly.

Liver damage

Liver damage has been reported after taking this medicine, especially when the medicine is misused. This could also be due to viral infections (chronic hepatitis C), alcohol abuse, anorexia or use of other medicines with the ability to harm your liver (see section 4). Regular blood tests may be conducted by your doctor to monitor the condition of your liver. Tell your doctor if you have any liver problems before you start treatment with Espranor.

Blood pressure

This product may cause your blood pressure to drop suddenly, causing you to feel dizzy if you get up too quickly from sitting or lying down.

Diagnosis of unrelated medical conditions

This medicine may mask pain symptoms that could assist in the diagnosis of some diseases. Do not forget to advise your doctor if you take this medicine.

Other medicines and Espranor

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Some medicines may increase the side effects of Espranor and may sometimes cause very serious reactions. Do not take any other medicines whilst taking Espranor without first taking to your doctor, especially:

• Concomitant use of Espranor and sedative medicines such as benzodiazepines or related drugs increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible.

However if your doctor does prescribe Espranor together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking and follow your doctor's dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms.

- Anti-depressants such as moclobemide, tranylcypromine, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, venlafaxine, amitriptyline, doxepin, or trimipramine. These medicines may interact with Espranor and you may experience symptoms such as involuntary, rhythmic contractions of muscles, including the muscles that control movement of the eye, agitation, hallucinations, coma, excessive sweating, tremor, exaggeration of reflexes, increased muscle tension, body temperature above 38°C. Contact your doctor when experiencing such symptoms.
- Other medicines that may make you feel sleepy which are used to treat illnesses such as anxiety, sleeplessness, convulsions / seizures, pain. These types of medicines will reduce your alertness levels making it difficult for you to drive and use machines. They may also cause central nervous system depression, which is very serious. Below is a list of

examples of these types of medicines:

- other opioid containing medicines such as methadone, certain pain killers and cough suppressants.
- antidepressants (used to treat depression) such as isocarboxazide and valproate may increase the effects of this medicine.
- sedative H₁ receptor antagonists (used to treat allergic reactions) such as diphenhydramine and chlorphenamine.
- barbiturates (used to cause sleep or sedation) such as phenobarbital, secobarbital.
- tranquilisers (used to cause sleep or sedation) such as chloral hydrate.
- Naltrexone may prevent Espranor from working. If you take naltrexone whilst you are taking Espranor you may experience a sudden onset of prolonged and intense withdrawal symptoms.
- Clonidine used to treat high blood pressure) may extend the effects of this medicine.
- Anti-retrovirals (used to treat AIDS) such as ritonavir, nelfinavir, indinavir may increase the effects of this medicine.
- Some antifungal agents (used to treat fungal infections) such as ketoconazole and itraconazole and certain antibiotics (macrolide) may extend the effects of this medicine.
- Some medicines may decrease the effect of Espranor. These include medicines used to treat epilepsy (such as carbamazepine and phenytoin) and medicines used to treat tuberculosis (rifampicin).

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Espranor with food, drink and alcohol

Espranor should not be taken at the same time as food or drink. You should not drink alcohol or take any medicines that contain alcohol while taking Espranor as this will increase the risk of drowsiness, respiratory depression and fatal overdose.

Pregnancy, breast-feeding and fertility

Tell your doctor if you are pregnant or intend to become pregnant.

When taken during pregnancy, particularly late pregnancy, medicines like Espranor may cause drug withdrawal symptoms including problems with breathing in your newborn baby. These symptoms may occur several days after birth.

Do not breast feed your baby whilst taking this medicine as Espranor passes into breast milk.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines

This medicine can cause drowsiness, which may be made worse if you also drink alcohol or take tranquilizers or anti-anxiety drugs. If you are drowsy, do not drive or operate

machinery.

Espranor contains aspartame

This medicine contains 0.5 mg aspartame in each 2 mg Oral Lyophilisate. This medicine contains 2.0 mg aspartame in each 8 mg Oral Lyophilisate.

Aspartame is a source of phenylalanine. It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.

3. How to take Espranor

Always take Espranor exactly as your doctor or pharmacist has told you. You should check with your doctor or pharmacist if you are not sure.

When to start taking Espranor

Starting Espranor treatment if you are dependent on heroin or a short acting opioid – your first dose of Espranor should be taken at least 6 hours after you last used the opioid or when signs of withdrawal appear.

Starting Espranor treatment if you are dependent on methadone or a long acting opioid – you will not start treatment with this medicine until your daily dose of methadone is 30 mg a day or less. The first dose of Espranor should be taken when signs of withdrawal appear, but not less than 24 hours after you last used methadone.

For the first 24 hours of treatment, you may feel uncomfortable with some mild opiate withdrawal symptoms e.g. sweating, feeling sick (see section 4 Possible side effects).

How much to take


Your doctor will decide what dose you need to start treatment with. During treatment your doctor will adjust your dose depending upon your response. The maximum dose is 18 mg daily. After a period of successful treatment, your doctor may gradually reduce your dose and depending on your condition, may stop it altogether.

Do not suddenly stop taking Espranor as this may lead to withdrawal symptoms.


Instructions for use

Take Espranor **by placing ON your tongue**, not under your tongue.


Espranor is sensitive to moisture. Make sure your hands are dry before handling the wafer. Take the wafer by following the instructions below:




1. Tear a square off the blister pack along the perforated lines.



2. The foil is easily peelable. Do not force the wafer through the foil as it is fragile and can easily break. Instead, fold back the foil and then peel it off.



3. Remove the wafer carefully from the foil and take out from the packaging immediately.



4. Place the wafer on the tongue and close your mouth. Allow it to remain there for a few seconds until it has dissolved. Try to avoid swallowing during the first 2 minutes. Do not eat or drink for at least 5 minutes.

If you take more Espranor than you should

Tell your doctor immediately or contact your nearest hospital casualty department. Remember to take the pack and any remaining wafers with you.

If you forget to take Espranor

You should tell your doctor and follow their instructions. Do not take a double dose to make up for the missed dose, unless your doctor tells you to.

If you stop taking Espranor

Do not suddenly stop taking the wafers unless told to do so by your doctor, as this may cause withdrawal symptoms.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everyone gets them.

Tell your doctor immediately and seek urgent medical attention if you experience any of the following serious effects, such as:

- sudden wheezing, difficulty breathing, swelling of the eyelids, face, tongue, lips, throat or hands; rash or itching especially those covering your whole body. These may be signs of a life-threatening allergic reaction.
- if you start to breath more slowly or weakly than expected (respiratory depression).
- if you start to feel faint, as this may be a sign of low blood pressure.
- severe fatigue (tiredness), have no appetite or if your skin or eyes look yellow. These may be symptoms of liver damage.

Other side effects may include:

Very common side effects (may affect more than 1 in 10 people) include: Insomnia (inability to sleep), feeling or being sick (nausea), hyperhidrosis (sweating), headache, drug withdrawal syndrome, pain.

Common side effects (may affect up to 1 in 10 people) are:

Swollen arm or leg, tiredness, drowsiness, anxiety, nervousness, tingling, depression, abnormal thinking, increased tearing (watering eyes) or other tearing disorder, blurred vision, flushing, palpitations, widening of blood vessel, migraines, sore throat and painful swallowing, cough, upset stomach or other stomach discomfort, diarrhoea, flatulence, vomiting, rash, joint pain, muscle pain, muscle spasms, abdominal pain, back pain, infection, chills, chest pain, fever, feeling of general discomfort, faintness and dizziness, bone pain, bronchitis, constipation, decreased appetite, dry mouth, menstrual cramping/painful menstruation, dyspnoea, hostility, hypertonia (increase in muscle tension), influenza, swollen glands (lymph nodes), large pupil size, neck pain, paranoia, change of colour, appearance or texture of the skin, tooth disorder, tremor, yawning, agitation, gastrointestinal disorders.

Side effects with unknown frequency (frequency cannot be estimated from the available data) include:

Drug dependence, drug withdrawal syndrome neonatal, seeing or hearing things that are not there (hallucinations), drop in blood pressure on changing position from sitting or lying down to standing, whirling or spinning sensation, unable or inability to urinate, redness, pain or swelling at the point of application (e.g. injection site), liver injury with or without jaundice, abnormal liver functional test, inflammation of the inner layer of the heart

If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

If you are not sure what the side effects listed are, ask your doctor to explain them to you.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via HPRA Pharmacovigilance, Website: www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Espranor

Keep this medicine out of the sight and reach of children

Do not use this medicine after the expiry date, which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

Store in the original package (blister) to protect from light and moisture. This medicinal product does not require any special temperature storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Espranor contains:

- The active substance is buprenorphine . Each oral lyophilisate (wafer) contains 2 mg or 8 mg of buprenorphine (as hydrochloride).
- The other ingredients are gelatine, mannitol, aspartame, mint flavour and citric acid.

What Espranor looks like and the contents of the pack

Espranor 2 mg oral lyophilisate is a white to off-white circular oral lyophilisate (wafer) marked with "M2" on one side.

Espranor 8 mg oral lyophilisate is a white to off-white circular oral lyophilisate (wafer) marked with "M8" on one side.

Your medicine is available in blisters containing 7 x 1 oral lyophilisates or 28 x 1 oral lyophilisates in an outer carton.

Not all pack sizes may be marketed.

Marketing Authorisation Holder:

Ethypharm

194, Bureaux de Ia Colline, Bâtiment D 92213, Saint-Cloud Cedex France.

Manufacturer - Batch Release Site:

Macarthys Laboratories Limited T/A Martindale Pharma Bampton Road Harold Hill Romford, Essex RM3 8UG United Kingdom

Ethypharm Chemin de la Poudrière, Le Grand Quevilly, 76120, France

This medicinal product is authorised in the Member states of the EEA under the following names:

Ireland	Espranor 2 mg Oral Lyophilisate
	Espranor 8 mg Oral Lyophilisate
United Kingdom	Espranor 2 mg oral lyophilisate
	Espranor 8 mg oral lyophilisate
Sweden	Espranor 2 mg frystorkad tablett
	Espranor 8 mg frystorkad tablett
France	OROBUPRE 2 mg lyophilisat oral
	OROBUPRE 8 mg lyophilisat oral

This leaflet was last revised in September 2022.